News
MBRX
4.524
+5.69%
0.244
Moleculin's acute myeloid leukemia treatment gets EMA's orphan drug designation
Moleculin Biotech's acute myeloid leukemia treatment gets EMA's orphan drug designation for the treatment of AML. Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. FDA. The European Medicines Agency has granted Orphan Drugs Designation to the drug.
Seeking Alpha · 1d ago
Moleculin Biotech’s Annamycin Granted Orphan Drug Status in EU
TipRanks · 1d ago
EUROPEAN MEDICINES AGENCY (EMA) GRANTS ORPHAN DRUG DESIGNATION FOR MOLECULIN'S TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)
Reuters · 1d ago
Weekly Report: what happened at MBRX last week (0408-0412)?
Weekly Report · 4d ago
Moleculin Biotech Price Target Maintained With a $40.00/Share by Roth MKM
Dow Jones · 6d ago
Moleculin Biotech Is Maintained at Buy by Roth MKM
Dow Jones · 6d ago
Roth MKM Maintains Buy on Moleculin Biotech, Maintains $40 Price Target
Benzinga · 6d ago
Moleculin Biotech Reveals Positive Anti-cancer Data For Annamycin With Non-cardiotoxic Effects
NASDAQ · 04/10 13:23
Moleculin Biotech Reveals Promising Annamycin Cancer Drug Data
TipRanks · 04/10 12:42
MOLECULIN BIOTECH- CO RECEIVED LETTER FROM NASDAQ NOTIFYING COMPANY THAT IT HAD REGAINED COMPLIANCE WITH BID PRICE RULE 5550(A)(2)
Reuters · 04/08 21:16
Weekly Report: what happened at MBRX last week (0401-0405)?
Weekly Report · 04/08 10:36
Weekly Report: what happened at MBRX last week (0325-0329)?
Weekly Report · 04/01 10:35
Health Care Sector Update for 03/27/2024: MBRX, LIXT, MRK, MRNA, BX
NASDAQ · 03/27 19:57
Moleculin gets U.S. patent issue notification for annamycin targeting unmet need in AML
Moleculin gets U.S. Patent issue notification for annamycin targeting unmet need in AML. Moleculin's novel candidate for the treatment of acute myeloid leukemia (AML) uses a unique lipid-based delivery technology. The company has additional patent applications pending.
Seeking Alpha · 03/27 13:22
Moleculin Biotech Secures New Patent for Annamycin Preparation
TipRanks · 03/27 13:22
Moleculin Biotech Is Maintained at Buy by Maxim Group
Dow Jones · 03/26 13:33
Moleculin Biotech Price Target Cut to $20.00/Share From $45.00 by Maxim Group
Dow Jones · 03/26 13:33
Maxim Group Maintains Buy on Moleculin Biotech, Lowers Price Target to $20
Benzinga · 03/26 13:24
Moleculin Biotech Shares Corporate Update Presentation
TipRanks · 03/25 19:12
Moleculin Biotech Announces Clinical Program Progress Updates
TipRanks · 03/25 11:42
More
Webull provides a variety of real-time MBRX stock news. You can receive the latest news about Moleculin Biotec through multiple platforms. This information may help you make smarter investment decisions.
About MBRX
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).